Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?
- 1.3k Downloads
While any study can be criticized, the results of Z0011 clearly show that sentinel lymph node biopsy (SLNB) alone without axillary lymph node dissection (ALND) results in extremely low locoregional recurrence and excellent overall survival comparable to completion ALND. The observed results in this trial with SLNB alone were excellent. A prospective randomized study with results such as Z0011 should alter therapy. The skilled clinician must utilize his or her experience and the prospective randomized data of this study to improve patient care for women with breast cancer. On the other hand, ALND continues to be the standard of care for positive nodes in the axilla, with lymph node status as the most important prognostic indicator in overall survival (OS) and disease-free survival (DFS) in the management of early stage breast cancer. The advent of sentinel lymph node resection (SLNR) is challenging this notion. There is evidence to support the need for regional control of the axilla as a preventative means for locoregional recurrence and improvement in DFS. ALND is both a diagnostic and therapeutic approach that not only decreases rates of locoregional recurrence, but also guides further treatment strategies. Currently, there are no definable criteria that completely prevent patients from benefiting from ALND in the setting of metastatic disease to the axilla. It is, therefore, clear that ALND should be strongly considered in the management of the SLN-positive axilla. SLNR has its role in the management of early stage breast cancer, but whether SLNR alone should replace ALND is yet to be determined.
KeywordsAxillary dissection Sentinel lymph node Breast cancer Biopsy Axilla
- 2.Giuliano AE, Kirgan DM, Guenther JM et al. (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–8; discussion 398–401Google Scholar
- 7.Moore MP, Kinne DW (1996) Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Important Adv Oncol 245–50Google Scholar
- 9.McMasters KM, Wong SL, Chao C et al. (2001) Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 234:292–9; discussion 299–300Google Scholar
- 10.Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRefGoogle Scholar
- 12.Pazaiti A, Fentiman IS (2011) Which patients need an axillary clearance after sentinel node biopsy? Int J Breast Cancer 2011:195892. doi: 10.4061/2011/195892
- 16.Giuliano AE, McCall L, Beitsch P et al. (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–32; discussion 432–3Google Scholar
- 20.Whelan T, Olivotto I, Ackerman J (2011) NCIC-CTG MA.20 an intergroup trial of regional nodal irradiation (RNI) in early stage breast cancer (suppl; Abstr LBA1003). J Clin Oncol 29:80sGoogle Scholar